Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 11:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 17,839 matching trials from the live ClinicalTrials.gov search.
Conditions
Multiple Myeloma in Relapse
Interventions
Talquetamab, Daratumumab
Drug
Lead sponsor
Larysa Sanchez
Other
Eligibility
70 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Multiple Myeloma
Interventions
Total Marrow Irradiation, Autologous Transplant, Melphalan, Filgrastim (G-CSF)
Radiation · Procedure · Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Breast Cancer
Interventions
Neratinib, Capecitabine
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
12
States / cities
Mobile, Alabama • Long Beach, California • Los Angeles, California + 9 more
Conditions
Multiple Myeloma
Interventions
Lenalidomide, bb2121, Cyclophosphamide, Fludarabine, leukapheresis
Drug · Biological · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
15
States / cities
Duarte, California • Palo Alto, California • San Francisco, California + 11 more
Conditions
Growth Hormone Deficiency
Interventions
Genotropin, somatrogon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Years to 17 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Sacramento, California • Aurora, Colorado • Centennial, Colorado + 11 more
Conditions
Pregnancy, Unexplained Infertility
Interventions
Letrozole (aromatase inhibitor), Clomiphene Citrate, Follicle Stimulating Hormone (gonadotropin)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 11 more
Completed Phase 2 Interventional Results available

A Study in Participants With Acute Leukemia

NCT01214603
Conditions
Leukemia
Interventions
LY2090314
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Chicago, Illinois • Minneapolis, Minnesota • Durham, North Carolina + 1 more
Conditions
Recurrent Melanoma, Stage IV Skin Melanoma
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Pharmacological Study, Stereotactic Body Radiation Therapy
Biological · Other · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Staccato Prochlorperazine Single Dose PK Study

NCT00610727
Conditions
Migraine
Interventions
Prochlorperazine 0.5 mg IV over 5 sec, Inhaled prochlorperazine 0.625 mg, Inhaled prochlorperazine 1.25 mg, Inhaled prochlorperazine 2.5 mg, Inhaled prochlorperazine 5 mg, Inhaled prochlorperazine 10 mg, Inhaled placebo, Prochlorperazine 10 mg IV over 5 sec
Drug
Lead sponsor
Nova Pneuma Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Conditions
Hepatitis C, Chronic
Interventions
Copegus, Pegasys, RO5024048
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
21
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 18 more
Conditions
Infections, Bacterial
Interventions
Gepotidacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
La Mesa, California
Conditions
Tri-specific Killer Engager, Solid Tumor, Advanced Solid Tumor
Interventions
GTB-5550
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122

NCT04634513
Conditions
Shigella Infection, Enterotoxigenic Escherichia Coli Infection
Interventions
strain CVD 1208S-122, Placebo
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 49 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Obesity
Interventions
NNC0519-0130, Placebo, Tirzepatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
49
States / cities
Mesa, Arizona • Little Rock, Arkansas • Searcy, Arkansas + 40 more
Conditions
CoronaVirus Disease-2019 (COVID-19)
Interventions
ABBV-47D11, Placebo for ABBV-47D11, ABBV-2B04, Placebo for ABBV-2B04
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
Glendale, California • Cutler Bay, Florida • Miami, Florida + 8 more
Conditions
Major Depressive Disorder
Interventions
Ketamine, Scopolamine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus
Interventions
Afimetoran, Placebo
Drug
Lead sponsor
Beeline Medicines Corporation
Industry
Eligibility
16 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
San Diego, California • DeBary, Florida • Missoula, Montana
Conditions
Diabetic Macular Edema (DME), Pars Plana Vitrectomy
Interventions
SAR 1118 0.1%, SAR 1118 1.0%, SAR 1118 5.0%
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Bladder Cancer
Interventions
Qapzola, Placebo
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 89 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Metastatic Colorectal Cancer
Interventions
Inavolisib, Bevacizumab, Cetuximab, Atezolizumab, Tiragolumab, SY-5609, Divarasib, FOLFOX, FOLFIRI, FoundationOne®Liquid CDx
Drug · Diagnostic Test
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 28 more
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
AZD2936
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, Minnesota • Fairfax, Virginia
Not yet recruiting Phase 2 Interventional

PFAS Clinical Trial

NCT07836023
Conditions
Environmental Exposure
Interventions
Cholestyramine, Centrum
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Atlanta, Georgia
Completed Not applicable Interventional Accepts healthy volunteers

The Efficacy of Reminders to Complete HPV Series

NCT01731496
Conditions
Completion of Three Dose Series of HPV, Improvement in Vaccine Intervals Between HPV Doses
Interventions
Telephone reminder, Text Message reminder
Other
Lead sponsor
University of Rochester
Other
Eligibility
10 Years to 21 Years
Enrollment
749 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
3
States / cities
Rochester, New York
Conditions
Osteoarthritis
Interventions
Meloxicam Test Capsules, Placebo Capsules
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
40 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
40
States / cities
Birmingham, Alabama • Carmichael, California • Pismo Beach, California + 31 more